The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
By Elaine Chen & Katie Palmer
Top news
This is the end of GLP-1 compounding as we know it
By Elaine Chen
Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats
By Dani Blum & Rebecca Robbins
Semaglutide injections will no longer be sold at compounding pharmacies after May 22
By Danielle Miller
Ozempic copies restricted after US judge denies injunction
All coverage
Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
By Anjalee Khemlani
The Wild East of semaglutide
By Marta Ewa Wosinska
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
By Annika Kim Constantino
US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutide
By Kevin Dunleavy
US patients lose access to cheaper weight-loss drugs as market for replicas winds down
By Hannah Kuchler
The Ozempic Legal Storm: What Med Spa Owners Need to Know
By Sara Shikhman
Denver healthcare providers express concerns about patients losing access to weight loss medications
By Nicole Brady
Novo Nordisk scores court win against GLP-1 copycat compounders
By Kimberly Redmond
Judge Says FDA Can Take Ozempic Off Shortage List
By Andrew Karpan
FDA Halts Sale of Compounded Semaglutide Injections, Phoenix Pharmacy Owner Voices Concern
By Kim Tran
Judge Rules Against Semaglutide Compounders After Shortage Declared Over
By Tristan Cesar Manalac
FDA stops sale of generic versions of Ozempic and Wegovy: What it means for patients
By Brittany Miller
Ozempic compounders suffer fresh legal setback (NVO:NYSE)
By Dulan Lokuwithana
Ozempic copies restricted after US judge denies injunction
By Patrick Wingrove & Dan Levine
Ozempic copies restricted after US judge denies injunction
By Patrick Wingrove & Dan Levine
FDA stops sale of generic versions of Ozempic and Wegovy: What it means for patients
By Brittany Miller
Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy - Novo Nordisk (NYSE:NVO)
By Vandana Singh
Ozempic copies restricted after US judge denies injunction
By Dan Levine & Patrick Wingrove
Ozempic copies restricted after US judge denies injunction
By Dan Levine & Patrick Wingrove